Critical Analysis: Second Sight Medical Products (EYES) vs. Its Rivals
Second Sight Medical Products (NASDAQ: EYES) is one of 19 publicly-traded companies in the “Medical Devices & Implants” industry, but how does it compare to its rivals? We will compare Second Sight Medical Products to related companies based on the strength of its dividends, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.
Valuation & Earnings
This table compares Second Sight Medical Products and its rivals top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Second Sight Medical Products||$3.98 million||-$33.17 million||-3.05|
|Second Sight Medical Products Competitors||$1.67 billion||$207.58 million||72.05|
This table compares Second Sight Medical Products and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Second Sight Medical Products||-565.12%||-184.87%||-137.77%|
|Second Sight Medical Products Competitors||-94.04%||-85.92%||-27.88%|
Volatility & Risk
Second Sight Medical Products has a beta of 3.67, indicating that its stock price is 267% more volatile than the S&P 500. Comparatively, Second Sight Medical Products’ rivals have a beta of 0.47, indicating that their average stock price is 53% less volatile than the S&P 500.
This is a summary of current recommendations for Second Sight Medical Products and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Second Sight Medical Products||0||0||1||0||3.00|
|Second Sight Medical Products Competitors||112||734||1028||10||2.50|
Second Sight Medical Products currently has a consensus price target of $5.00, indicating a potential upside of 156.41%. As a group, “Medical Devices & Implants” companies have a potential upside of 39.26%. Given Second Sight Medical Products’ stronger consensus rating and higher possible upside, analysts plainly believe Second Sight Medical Products is more favorable than its rivals.
Insider & Institutional Ownership
12.8% of Second Sight Medical Products shares are held by institutional investors. Comparatively, 54.8% of shares of all “Medical Devices & Implants” companies are held by institutional investors. 34.7% of Second Sight Medical Products shares are held by company insiders. Comparatively, 10.3% of shares of all “Medical Devices & Implants” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Second Sight Medical Products rivals beat Second Sight Medical Products on 7 of the 12 factors compared.
Second Sight Medical Products Company Profile
Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. It does not restore normal vision and it does not slow or reverse the progression of the disease. The Company’s Argus II System employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals. The Argus II System works by converting video images captured by a miniature camera housed in a patient’s glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes that are implanted on the surface of the retina.
Receive News & Ratings for Second Sight Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.